Prognostic role of serum carcinoembryonic antigen in patients receiving liver resection for colorectal cancer liver metastasis: A meta-analysis

Abstract

BACKGROUND

Carcinoembryonic antigen (CEA) is a broad-spectrum tumor marker for differential diagnosis, monitoring, and response assessment of a variety of malignancies.

AIM

To evaluate whether serum CEA could predict the prognosis in patients with colorectal cancer liver metastasis (CRCLM) before and after liver resection (LR).

METHODS

PubMed, Embase, Cochrane, and Web of Science were systematically searched to retrieve literature, with a search cut-off date of February 27, 2023. Articles were strictly screened for inclusion according to pre-specified inclusion and exclusion criteria. Data were pooled and analyzed using Stata 16.0.

RESULTS

This meta-analysis included 36 studies involving a total of 11143 CRCLM patients. The results showed that a high pre-LR serum CEA level was correlated with poor overall survival (OS) [hazard ratio (HR) = 1.61, 95% confidence interval (CI): 1.49-1.75, P < 0.001] and recurrence-free survival (HR = 1.27, 95%CI: 1.11-1.45, P < 0.001) in CRCLM patients. A high post-LR serum CEA level predicted poor OS (HR = 2.66, 95%CI: 2.10-3.38, P < 0.001). A comparison by treatment modality, analysis modality, patient source, and cutoff-value showed that overall, high preoperative and postoperative serum CEA levels remained correlated with a poor prognosis.

CONCLUSION

This study concluded that high pre-LR and post-LR serum CEA levels were significantly correlated with a poor prognosis in CRCLM patients.

Key Words: Carcinoembryonic antigen; Colorectal cancer liver metastasis; Liver resection; Meta-analysis

Core Tip: Carcinoembryonic antigen (CEA) is a broad-spectrum tumor marker for differential diagnosis, monitoring, and response assessment of a variety of malignancies. This meta-analysis was aimed at evaluating whether serum CEA could predict the prognosis in patients with colorectal cancer liver metastasis before and after liver resection. Articles were strictly screened for inclusion according to pre-specified inclusion and exclusion criteria.

INTRODUCTION

Cancer is a major public health problem worldwide, and colorectal cancer (CRC), one of the malignancies of the digestive system[1]. Globally, there are more than 1.85 million new cases of CRC and 850000 deaths each year[2]. Recurrence and metastasis are inherent characteristics of cancer. Metastasis and infiltration can cause changes in the affected organs, thereby resulting in increased difficulty in treatment and a poor prognosis[3,4]. The liver is the major target organ of hematogenous metastasis in patients with CRC in the intermediate to advanced stages, and hematogenous liver metastasis is the leading cause of a poor prognosis or even death[5,6]. The main treatments for CRC liver metastasis (CRCLM) are surgical resection, local therapy, and chemotherapy, in which liver resection (LR) is considered the preferred curative treatment for CRCLM[7,8]. Compared with many other abdominal surgeries, LR is a complex procedure with inherent risks, such as long operative time, increased risk for bleeding, pulmonary complications, post-hepatectomy liver failure and kidney failure[9]. The incidence and mortality at 30 d after LR were reported to be 14%-55% and 0%-11.9%, respectively, with a 5-year survival rate of only about 30%-50% and a recurrence rate of up to 60%[10-12], so it will be valuable to find appropriate prognostic markers to predict the outcome in CRCLM patients after LR.

The main prognostic markers of CRC that are widely used currently in clinical practice are carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA). The serum CA19-9 level is often affected by a variety of neoplastic disorders of the gastrointestinal tract and benign biliary diseases (such as primary sclerosing cholangitis or bile duct obstruction due to common bile duct stones), which means that CA19-9 may not be an ideal marker for CRC patients[13]. CEA, also known as CD66e, is a glycoprotein consisting of about 100 amino acid residues, produced and secreted by gastrointestinal epithelial cells, and it is one of the most widely used tumor markers worldwide[14]. It had been reported that the initial level of CEA was closely related to the prognosis of CRC patients after LR[15]. It was shown that the serum CEA level was closely related to the proliferation, growth and degree of infiltration of tumor cells, and of certain value in the diagnosis of CRCLM[16,17], so it can be used as an indicator for early diagnosis and prognosis of CRCLM[18,19]. The CEA level has been a long-established tumor marker, recommended by the American Society of Clinical Oncology as a marker of CRC[20], and included in the tumor-node-metastasis system (so-called stage C) to provide additional prognostic information[21]. Most clinical guidelines recommend measuring preoperative and postoperative serum CEA levels to predict the prognosis of CRC[22-25]. It was also shown that postoperative CEA was an important prognostic factor for CRC[26-28]. In addition, it was confirmed that preoperative and postoperative serum CEA levels were correlated with the outcome in CRC patients, and an increased postoperative CEA level was possibly of more significant prognostic value than an increased preoperative CEA level[29].

Therefore, this paper explored whether serum CEA in CRCLM patients receiving LR played a significant predictive and prognostic role before and after surgery by summarizing currently available research data, so as to provide a scientific basis for further improving the prognosis in CRCLM patients.

MATERIALS AND METHODS

Search strategy

PubMed, Embase, Cochrane and Web of Science were searched with a time frame until February 27, 2023. The keywords mainly included “Carcinoembryonic Antigen”, “Colorectal Neoplasms” and “liver metastasis”, and search was based on a combination of subject headings and free-text words. The search strategy is detailed in Supplementary Table 1.

Inclusion and exclusion criteria

Studies meeting all of the following criteria were included: (1) Study subjects: Adult patients definitively diagnosed with CRC with liver metastasis according to pathological histology who have received LR; (2) Exposure: Clearly reported pre-LR and post-LR serum CEA levels; (3) Reported the effect of serum CEA levels on at least one of the following outcome measures: Overall survival (OS) (time from the start of randomization grouping to death due to any cause), disease-free survival (DFS) (time from the start of randomization until disease recurrence or death of the patient due to disease progression), and recurrence-free survival (RFS) (time from randomization grouping to evidence of disease recurrence); and (4) Study type: Cohort studies.

Studies meeting any of the following criteria were excluded: (1) Duplicate studies using the same populations or overlapping databases; (2) Meta-analyses, systematic reviews, reviews, letters, responses, conference abstracts, case reports, guidelines, consensuses; and (3) Animal or in vitro experiments.

Literature screening

The retrieved studies were imported into Endnote X9, and then, duplicate references were excluded automatically by the software and manually. Subsequently, initial screening was performed by reading the titles and abstracts, next, the full texts of studies that passed initial screening were downloaded and then read for re-screening to select the original studies that finally met the inclusion criteria for a meta-analysis. The literature screening process was carried out independently by two investigators (Tang F and Huang CW), and then, the studies included by them were cross-checked. Any disputes were resolved with the assistance of a third investigator (Wu FX).

Data extraction

After literature screening was completed, an Excel data extraction form specific to this study was developed to summarize the information on the included articles as follows: (1) General information: The first author, year of publication, country, study type, age and gender in a study group; and (2) Study characteristics: Interventions, exposure levels, the analysis modality, risk ratios for outcome measures with 95% confidence intervals (95%CIs).

For studies with incomplete data, attempts were made to contact the corresponding authors of the studies. Two appraisers (Tang ZH and Lu SL) independently extracted information from the eligible studies, and any disagreements between them were resolved through a third person (Bai T).

Quality assessment

Two reviewers (Li XZ and Zhang B) independently assessed the methodological quality of each included cohort study using eight items from three modules of the Newcastle-Ottawa Scale (NOS)[30]. An assessment consisted of three main parts: selection of study populations (0-4), comparability of groups (0-2), and outcome measures (0-3). Studies with total scores ≥ 6 were considered of high quality. Any disagreements that arose were resolved through discussion or, if necessary, arbitration by a third person (Huang Q).

Statistical analysis

A meta-analysis was performed using Stata16.0. Hazard ratios (HRs) and 95%CIs for serum CEA levels as a prognostic indicator were extracted directly from the included articles, or univariate data were estimated for some articles using Engauge 11.3 and Excel tables for calculating HRs and 95%CIs according to the methods illustrated by Parmar et al[31] and Tierney et al[32], if multiple estimates were reported in the same article, the results of multivariate analysis adjusted for confounding factors would be selected. Heterogeneity among the included studies was assessed using I²[33]. A fixed-effects model was used if I² < 50% (low heterogeneity), and a random-effects model was used if I² ≥ 50% (high heterogeneity). To investigate the sources of heterogeneity, subgroup analysis was performed by patient source, treatment modality, analysis modality, and cut-off value > 5 ng/mL or not, and further sensitivity analysis was performed to investigate the stability of the study results. Sensitivity analysis was aimed at assessing the effect of individual studies on the overall outcome by excluding 1 study at a time. Publication bias was assessed by Begg’s and Egger’s tests. If bias existed, correction would be performed using the trim-and-fill method. All P values were two-sided, and P < 0.05 was set to indicate a statistically significant difference.

RESULTS

Search results

A total of 6541 studies were collected by searching the four databases. A total of 2424 duplicates were excluded automatically and manually, and 4009 of the remaining 4117 studies were excluded after reading the titles and abstracts. The full texts of the remaining 108 articles were read and re-screened. Finally, 36 articles met all inclusion criteria and were included. The specific reasons for exclusion and the literature search process are shown in Figure 1.

Figure 1 Literature screening process. CEA: Carcinoembryonic antigen.

Characteristics of the included studies

Table 1 summarizes the general characteristics of the included studies. A total of 36 studies were included, involving 11143 subjects, composed of 6769 men and 4374 women. Of these studies, 19 were from Asia[34-52], 11 from Europe[53-63], 4 from North America[64-67], and one study each from Oceania[68] and South America[69]. The years of publication ranged from 1994 to 2023. A total of 31 studies discussed pre-LR CEA levels, and 9 studies investigated the effect of post-LR CEA levels on prognosis in CRCLM patients. The cut-off values for CEA ranged from 4.9 ng/mL to 200 ng/mL. The results of quality assessment based on the NOS are detailed in Supplementary Table 2, with all studies scored more than 6 and being of high quality.

Table 1 Basic features of the included literature.

No.	Ref.	Country	Study type	Treatment	Univariate/multivariate analysis	Cut-off (ng/mL)	Sample size	Age	Male/female	Outcomes	Nos
1	Meng et al[34], 2021	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	100	234	Range (n): < 65, 164; ≥ 65, 70	126/108	OS	9
2	Okimoto et al[35], 2017	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	134	Median (range): 63 (30-87)	90/44	OS	8
3	Kamphues et al[53], 2021	Germany	Cohort Study	Hepatectomy	Multivariate	6.15	1643	Median (range): 62 (18-90)	1018/625	OS	7
4	Kawahara et al[36], 2018	Japan	Cohort study	Hepatectomy	Univariate	5/50	66	Median (range): 65.2 (31-80)	45/21	RFS	7
5	Hof et al[54], 2016	The Netherlands	Cohort study	Hepatectomy	Multivariate	200	431	mean ± SD: 62.9 ± 9.4	264/167	OS	8
6	Chiang et al[37], 2019	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	490	Median (range): 60.3 (28.8-88.0)	332/158	RFS, OS	8
7	Peltonen et al[55], 2018	Finland	Cohort study	Hepatectomy + chemotherapy	Univariate	5	168	Median (range): 64.3 (36.3-81.5)	101/67	OS, DFS	8
8	Lu et al[38], 2016	China	Cohort study	Hepatectomy + chemotherapy	Univariate	5	141	Median (range): 60 (20-82)	92/49	OS	7
9	John et al[56], 2013	United Kingdom	Cohort study	Hepatectomy + chemotherapy	Univariate	200	432	Median (range): 64.5 (29-85)	289/143	OS	7
10	Yi et al[39], 2013	Korea	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	76	Median (range): 57(31-75)	47/29	DFS	8
11	Gervaz et al[57], 2000	Switzerland	Cohort study	Hepatectomy	Univariate	4	49	≥ 18	35/14	OS	7
12	Sasaki et al[40], 2005	Japan	Cohort study	Hepatectomy	Multivariate	10	103	Range (n): ≤ 32, 164; > 60, 71	56/47	OS	9
13	Wang et al[41], 2017	China	Cohort study	Hepatectomy + chemotherapy	Multivariate	5	159	Median (range): Non-targeted therapy group 52 (35-83); bevacizumab combined treatment group 43 (32-71); cetuximab combined treatment group 59 (28-76)	101/58	RFS, OS	8
14	Takamizawa et al[42], 2022	Japan	Cohort study	Hepatectomy	Multivariate	5	554	Median (range): 62 (21-88)	358/196	RFS, OS	9
15	Masuda et al[64], 2018	United States	Cohort study	Hepatectomy + RFA	Multivariate	30	116	mean ± SD: tumors ≥ 4, 58.7 ± 10.6; tumors < 4, 57.6 ± 12.0	74/42	OS	7
16	Zhang et al[43], 2017	China	Cohort study	Hepatectomy	Multivariate	100	102	Range (n): < 60, 66; ≥ 60, 36	63/39	OS	9
17	Ishii et al[44], 2022	Japan	Cohort study	Hepatectomy	Univariate	5	90	Median (range): High CII 65 (31-87); low CII 65 (32-82)	58/32	RFS, OS	7
18	Tanaka et al[45], 2008	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	12	79	Range (n): ≥ 60, 46; < 60, 33	49/30	OS	9
19	Sasaki et al[65], 2016	United States	Cohort study	Hepatectomy + RFA	Multivariate	30	485	Median (IQR): 58.5 (49.1-66.5)	290/195	OS	8
20	Chen et al[46], 2020	China	Cohort study	Hepatectomy + chemotherapy	Univariate	10	141	Median (IQR): 55 (49.0-62.0)	92/49	PFS, OS	7
21	Montalti et al[58], 2015	Belgium	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	114	mean ± SD: 66.4 ± 0.89	78/36	OS, RFS	6
22	Reddy et al[67], 2009	United States	Cohort study	Hepatectomy + chemotherapy	Multivariate	200	499	Median (range): 57(49-66)	294/205	OS	6
23	Reddy et al[66], 2009	United States	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	230	Median (range): 61(33-83)	137/93	OS	7
24	Li et al[47], 2023	China	Cohort study	Hepatectomy + chemotherapy	Univariate	200	431	Median (IQR): 59 (49-68)	282/149	RFS, OS	7
25	Niu et al[68], 2007	Australia	Cohort study	Hepatectomy	Multivariate	5	315	mean ± SD: 62 ± 11	239/176	OS	6
26	Polivka et al[59], 2020	The Czech Republic	Cohort study	Hepatectomy	Multivariate	4.9	71	Median (range): 62.7 (29-77)	29/42	DFS, OS	6
27	Takeda et al[48], 2022	Japan	Cohort study	Hepatectomy + chemotherapy	Multivariate	10	238	Range (n): < 60, 123; ≥ 60, 115	184/54	OS	8
28	Dumarco et al[69], 2023	Brazil	Cohort study	Hepatectomy	Multivariate	20	137	Median (range): 58.2 (23-87)	75/62	OS, DFS	8
29	Kim et al[49], 2019	Korea	Cohort study	Hepatectomy + chemotherapy	Multivariate	100	83	mean ± SD: 59.5 ± 10.0	62/21	OS	8
30	Peng et al[50], 2017	China	Cohort study	Hepatectomy	Univariate	200	150	Median (range): 58 (20-82)	97/53	RFS, OS	7
31	Imai et al[60], 2016	France	Cohort study	Hepatectomy	Multivariate	50	846	Median (range): 61 (28-89)	502/344	OS	8
32	Pawlik et al[61], 2005	Switzerland	Cohort study	Hepatectomy	Multivariate	200	566	Median 60	221/345	OS	6
33	Miki et al[51], 2018	Japan	Cohort study	Hepatectomy	Multivariate	5	73	Median (range): 59 (27-82)	49/24	DFS	8
34	Hohenberger et al[62], 1994	Germany	Cohort study	Hepatectomy	Univariate	5	166	Median (range): 59 (30-79)	99/67	OS	7
35	Arru et al[65], 2008	Italy	Cohort study	Hepatectomy	Multivariate	5/200	297	Range (n): < 65, 177; ≥ 65, 120	171/126	OS	8
36	Yoshino et al[52], 2022	Japan	Cohort study	Hepatectomy	Multivariate	5	633	Median (range): 64.0 (27.0-92.0)	414/219	RFS, OS	8

OS: Overall survival; DFS: Disease-free survival; RFS: Recurrence-free survival; IQR: Interquartile range; RFA: Radiofrequency ablation; PFS: Progression-free survival.

Meta-analysis of pre-LR serum CEA levels to predict prognosis in CRCLM patients

Overall and subgroup analysis of OS: A total of 28 studies reported pre-LR serum CEA levels to predict OS in patients[34,35,38,40-50,53,55,56,58,59,61-67,69]. The heterogeneity test results showed I² = 34.9%, so a fixed-effects model was used for analysis. The results showed that high CEA levels before treatment were correlated with poor OS, and the differences were statistically significant (HR = 1.61, 95%CI: 1.49-1.75, P < 0.001) in Figure 2A and Table 2.

Figure 2 Forest plot of the correlation between high preoperative serum carcinoembryonic antigen levels and overall survival, disease-free survival, recurrence-free survival. A: Forest plot of the correlation between high preoperative serum carcinoembryonic antigen (CEA) levels and overall survival. In the study of Arru et al[65], the hazard ratio (HR) [95% confidence interval (CI)] for CEA levels > 5 ng/mL was 2.10 (1.10-3.90), and the HR (95%CI) for CEA levels < 5 ng/mL was 1.60 (0.70-3.70); B: Forest plot of the correlation between high preoperative serum CEA levels and disease-free survival; C: Forest plot of the correlation between high preoperative serum CEA levels and recurrence-free survival. In the study of Kawahara et al[36], the HR (95%CI) for CEA levels > 50 ng/mL was 2.15 (0.94-4.94), and the HR (95%CI) for CEA levels < 50 ng/mL was 1.51 (0.57-3.95). HR: Hazard ratio; CI: Confidence interval.

Table 2 Summary of meta-analysis results.

Outcome	Number of studies	Model	Hazard ratio (95%CI)	P value	Heterogeneity (P value, I2)
Pre-LR
OS	28	Fixed	1.61 (1.49-1.75)	< 0.001	0.035, 34.9%
Region
Europe	8	Fixed	1.60 (1.41-1.82)	< 0.001	0.086, 42.3%
Asia	15	Fixed	1.43 (1.25-1.63)	< 0.001	0.377, 6.8%
South America	1	Fixed	1.31 (0.78-2.20)	0.307	/
North America	4	Fixed	2.21 (1.82-2.69)	< 0.001	0.980, 0.0%
Treatment modality
LR alone	12	Fixed	1.46 (1.31-1.64)	< 0.001	0.405, 4.1%
LR + chemotherapy	14	Fixed	1.74 (1.52-1.98)	< 0.001	0.053, 41.4%
LR + radiofrequency ablation	2	Fixed	2.18 (1.63-2.91)	< 0.001	0.844, 0.0%
Analysis modality
Multivariate	20	Fixed	1.70 (1.55-1.87)	< 0.001	0.099, 29.8%
Univariate	6	Fixed	1.23 (1.00-1.52)	0.053	0.618, 0.0%
Survival curve	2	Fixed	1.62 (1.24-2.13)	< 0.001	0.067, 70.2%
Cut-off
≤ 5 ng/mL	9	Fixed	0.32 (0.21-0.43)	< 0.001	0.570, 0.0%
5-50 ng/mL	11	Fixed	0.54 (0.42-0.66)	< 0.001	0.034, 48.7%
100 ng/mL	3	Fixed	0.60 (0.11-1.09)	0.017	0.407, 0.0%
200 ng/mL	6	Fixed	0.65 (0.45-0.84)	< 0.001	0.565, 0.0%
DFS	4	Random	1.49 (0.97-2.29)	0.067	0.109, 50.4%
Region
South America	1	Random	1.89 (1.13-3.15)	0.015	/
Asia	1	Random	1.27 (0.63-2.57)	0.507	/
Europe	2	Random	1.65 (0.55-4.93)	0.373	0.049, 74.2%
Treatment modality
LR alone	3	Random	1.81 (1.20-2.72)	0.005	0.340, 7.4%
LR + chemotherapy	1	Random	1.04 (0.71-1.53)	0.833	/
Analysis modality
Multivariate	3	Random	1.81 (1.20-2.72)	0.005	0.340, 7.4%
Univariate	1	Random	1.04 (0.71-1.53)	0.833	/
Cut-off
> 5 ng/mL	1	Random	1.89 (1.13-3.15)	0.015	/
≤ 5 ng/mL	3	Random	1.37 (0.80-2.35)	0.255	0.142, 48.7%
RFS	8	Fixed	1.27 (1.11-1.45)	< 0.001	0.117, 37.8%
Region
Asia	7	Fixed	1.25 (1.09-1.43)	0.001	0.101, 41.6%
Europe	1	Fixed	1.71 (0.90-3.24)	0.101	/
Treatment modality
LR alone	5	Fixed	1.32 (1.14-1.53)	< 0.001	0.176, 34.8%
LR + chemotherapy	3	Fixed	1.10 (0.83-1.47)	0.509	0.135, 50.1%
Analysis modality
Univariate	3	Fixed	1.07 (0.76-1.49)	0.709	0.569, 0.0%
Survival curve	1	Fixed	1.85 (0.99-3.47)	0.055	/
Multivariate	4	Fixed	1.29 (1.11-1.49)	0.001	0.030, 66.5%
Cut-off
≤ 5 ng/mL	5	Fixed	0.22 (0.08-0.37)	0.003	0.060, 55.7%
5-50 ng/mL	2	Fixed	0.62 (0.12-1.13)	0.016	0.669, 0.0%
200 ng/mL	2	Fixed	0.11 (-0.32 to 0.54)	0.615	0.313, 1.9%
Post-LR
OS	8	Random	2.66 (2.10-3.38)	< 0.001	0.002, 68.7%
Region
Asia	2	Random	2.63 (1.87-3.70)	< 0.001	0.040, 76.2%
Europe	5	Random	3.04 (2.10-4.40)	< 0.001	0.022, 65.1%
Oceania	1	Random	1.63 (1.09-2.42)	0.016	/
Treatment modality
LR + chemotherapy	2	Random	2.75 (1.70-4.44)	< 0.001	0.046, 74.8%
LR alone	6	Random	2.66 (1.91-3.69)	< 0.001	0.003, 71.9%
Analysis modality
Multivariate	5	Random	2.23 (1.79-2.78)	< 0.001	0.061, 55.7%
Survival curve	2	Random	4.40 (2.58-7.51)	< 0.001	0.215, 35.0%
Univariate	1	Random	3.68 (2.35-5.79)	< 0.001	/
Cut-off
≤ 5 ng/mL	6	Random	1.07 (0.78-1.37)	< 0.001	0.001, 74.9%
5-50 ng/mL	1	Random	0.74 (0.36-1.13)	< 0.001	/
200 ng/mL	1	Random	0.64 (0.10-1.17)	0.019	/
DFS	2	Fixed	3.23 (2.20-4.75)	< 0.001	0.182, 43.8%
RFS	2	Fixed	2.38 (2.05-2.77)	< 0.001	0.160, 49.3%

OS: Overall survival; DFS: Disease-free survival; RFS: Recurrence-free survival; CI: Confidence interval; LR: Liver resection.

Subgroup analysis was performed by patient source, treatment modality, analysis modality, and cut-off value of ≤ 5 ng/mL, 5-50 ng/mL, 100 ng/mL, 200 ng/mL. Subgroup analysis showed that high preoperative serum CEA levels remained a predictor of poor OS in CRCLM patients, regardless of whether they were from Asian (HR = 1.43, 95%CI: 1.25-1.63, P < 0.001), European (HR = 1.60, 95%CI: 1.41-1.82, P < 0.001), or North American (HR = 2.21, 95%CI: 1.82-2.69, P < 0.001) populations, as shown in Supplementary Figure 1 and Table 2.

High preoperative serum CEA levels remained a predictor of poor OS in CRCLM patients, regardless of whether they received LR alone (HR = 1.46, 95%CI: 1.31-1.64, P < 0.001), LR + chemotherapy (HR = 1.74, 95%CI: 1.52-1.98, P < 0.001), or LR + radiofrequency ablation (HR = 2.18, 95%CI: 1.63-2.91, P < 0.001), as shown in Supplementary Figure 2 and Table 2.

High preoperative serum CEA levels remained correlated with poor OS in CRCLM patients in both multivariate analysis (HR = 1.70, 95%CI: 1.55-1.87, P < 0.001) and survival curves (HR = 1.62, 95%CI: 1.24-2.13, P < 0.001), and the difference was statistically significant, whereas in univariate analysis, such correlation was not found (HR = 1.23, 95%CI: 1.00-1.52, P = 0.053), as shown in Supplementary Figure 3 and Table 2.

The results of subgroup analysis by cut-off values of ≤ 5 ng/mL (HR = 0.32, 95%CI: 0.21-0.43, P < 0.001), 5-50 ng/mL (HR = 0.54, 95%CI: 0.42-0.66, P < 0.001), 100 ng/mL (HR = 0.60, 95%CI: 0.11-1.09, P = 0.017), 200 ng/mL (HR = 0.65, 95%CI: 0.45-0.84, P < 0.001) also showed that high preoperative serum CEA levels were a predictor of poor OS in CRCLM patients, as shown in Supplementary Figure 4 and Table 2.

Overall and subgroup analysis of DFS: A total of 4 studies reported pre-LR serum CEA levels to predict DFS in patients[51,55,59,69]. The heterogeneity test results showed I² = 50.4%, so a fixed-effects model was used for analysis. Overall results showed no statistically significant correlation between pre-LR serum CEA and DFS in patients (HR = 1.49, 95%CI: 0.97-2.29, P = 0.067) (Figure 2B and Table 2). To investigate the sources of heterogeneity, subgroup analysis was performed by patient source, treatment modality, analysis modality, and cut-off value > 5 ng/mL or not. The results showed that treatment modality, analysis modality, and cut-off value classification possibly caused heterogeneity. High preoperative serum CEA levels in patients receiving LR alone were potentially correlated with shorter DFS (HR = 1.81, 95%CI: 1.20-2.72, P = 0.005). Multivariate analysis also showed that high preoperative CEA levels were correlated with poorer DFS (HR = 1.81, 95%CI: 1.20-2.72, P = 0.005). The results of subgroup analysis of the European patient group (HR = 1.65, 95%CI: 0.55-4.93, P = 0.373) and the cut-off values ≤ 5 ng/mL (HR = 1.37, 95%CI: 0.80-2.35, P = 0.255) suggested no such prognostic significance, as detailed in Supplementary Figures 5-8 and Table 2.

Overall and subgroup analysis of RFS: A total of 8 studies reported pre-LR serum CEA levels to predict RFS in patients[36,41,42,44,47,50,52,58]. The heterogeneity test results showed I² = 37.9%, so a fixed-effects model was used for analysis. The results showed that high preoperative serum CEA levels were correlated with poor RFS, and the difference was statistically significant (HR = 1.27, 95%CI: 1.11-1.45, P < 0.001), as shown in Figure 2C and Table 2.

Subgroup analysis was performed by patient source, treatment modality, analysis modality, and cut-off value of ≤ 5 ng/mL, 5-50 ng/mL, 200 ng/mL. The results of subgroup analysis showed that in the Asian patient population (HR = 1.25, 95%CI: 1.09-1.43, P = 0.001), high preoperative serum CEA levels predicted shorter RFS in the subgroup of patients receiving LR only (HR = 1.32, 95%CI: 1.14-1.53, P < 0.001), the subgroup of multivariate analysis (HR = 1.29, 95%CI: 1.11-1.49, P = 0.001), and the subgroup of cut-off values of ≤ 5 ng/mL (HR = 0.22, 95%CI: 0.08-0.37, P = 0.003) and 5-50 ng/mL (HR = 0.62, 95%CI: 0.12-1.13, P = 0.016). In contrast, such predictive ability was not significant in the subgroup receiving LR + chemotherapy (HR = 1.10, 95%CI: 0.83-1.47, P = 0.509), the subgroup of in univariate analysis (HR = 1.07. 95%CI: 0.76-1.49, P = 0.709), and the subgroup of cut-off values of 200 ng/mL (HR = 0.11, 95%CI: -0.32 to 0.54, P = 0.615), as shown in Supplementary Figures 9-12 and Table 2.

Meta-analysis of post-LR CEA levels to predict prognosis in CRCLM patients

Overall and subgroup analysis of OS: A total of 8 studies reported post-LR serum CEA levels to predict OS in patients[37,52,54,55,57,60,62,68]. The heterogeneity test results showed I² = 68.7%, so a fixed-effects model was used for analysis. The results showed that high post-LR CEA levels were correlated with poor OS, and the difference was statistically significant (HR = 2.66, 95%CI: 2.10-3.38, P < 0.001), as shown in Figure 3A and Table 2. To investigate the sources of heterogeneity, subgroup analysis was performed by patient source, treatment modality, analysis modality, and cut-off values of ≤ 5 ng/mL, 5-50 ng/mL, 200 ng/mL. The results showed that high postoperative serum CEA levels were a predictor of poor OS in CRCLM patients from Asia (HR = 2.63, 95%CI: 1.87-3.70, P < 0.001) and Europe (HR = 3.04, 95%CI: 2.10-4.40, P < 0.001), as shown in Supplementary Figure 13 and Table 2.

Figure 3 Forest plot of the correlation between high postoperative serum carcinoembryonic antigen levels and overall survival, disease-free survival, recurrence-free survival. A: Forest plot of the correlation between high postoperative serum carcinoembryonic antigen (CEA) levels and overall survival; B: Forest plot of the correlation between high postoperative serum CEA levels and disease-free survival; C: Forest plot of the correlation between high postoperative serum CEA levels and recurrence-free survival. HR: Hazard ratio; CI: Confidence interval.

High postoperative serum CEA levels were a predictor of poor OS in CRCLM patients receiving LR alone (HR = 2.66, 95%CI: 1.91-3.69, P < 0.001) and those receiving LR + chemotherapy (HR = 2.75, 95%CI: 1.70-4.44, P < 0.001), as shown in Supplementary Figure 14 and Table 2. Heterogeneity (I²) test results showed that the analysis modality might partially cause heterogeneity (I² = 55.7% in multivariate analysis; I² = 35.0% in the survival curve). Subgroup analysis showed that high postoperative serum CEA levels were correlated with poor OS in CRCLM patients, with statistically significant differences in both multivariate analysis (HR = 2.23, 95%CI: 1.79-2.78, P < 0.001) and survival curves (HR = 4.40, 95%CI: 2.58-7.51, P < 0.001), as shown in Supplementary Figure 15 and Table 2.

The results of subgroup analysis showed that high postoperative serum CEA levels were a predictor of poor OS in CRCLM patients regardless of cut-off values ≤ 5 ng/mL (HR = 1.07, 95%CI: 0.78-1.37, P < 0.001), 5-50 ng/mL (HR = 0.74, 95%CI: 0.36-1.13, P < 0.001) or 200 ng/mL (HR = 0.64, 95%CI: 0.10-1.17, P = 0.019), as shown in Supplementary Figure 16 and Table 2.

DFS: A total of 2 studies reported post-LR CEA levels to predict DFS in patients[39,55]. The heterogeneity test results showed I² = 43.8%, so a fixed-effects model was used for analysis. The results showed that high postoperative CEA levels were correlated with poor DFS, and the difference was statistically significant (HR = 3.23, 95%CI: 2.20-4.75, P < 0.001), as shown in Figure 3B and Table 2.

RFS: A total of 2 studies reported post-LR CEA levels to predict RFS in patients[37,52]. The heterogeneity test results showed I² = 49.3%, so a fixed-effects model was used for analysis. The results showed that high postoperative CEA levels were correlated with poor RFS, and the difference was statistically significant (HR = 2.38, 95%CI: 2.05-2.77, P < 0.001), as shown in Figure 3C and Table 2.

Sensitivity analysis and publication bias

Sensitivity analysis was performed by excluding each article one by one to investigate the stability of the merged HRs of preoperative OS, DFS, RFS, and postoperative OS. The results suggested that the results were stable with low sensitivity, as shown in Supplementary Figures 17-20.

Publication bias was assessed by Begg’s and Egger’s tests. Begg’s test results showed P (preoperative OS) = 0.209, P (preoperative RFS) = 0.754, and P (postoperative OS) = 0.536, all more than 0.05, as shown in Supplementary Figures 21-23. Egger’s test results showed P (preoperative OS) = 0.260, P (preoperative RFS) = 0.808, and P (postoperative OS) = 0.398, all more than 0.05, indicating no publication bias, as shown in Supplementary Figures 24-26.

DISCUSSION

Previous meta-analyses confirmed that increased preoperative CEA was correlated with the occurrence, progression, and prognosis of multiple cancers[70-72]. Although more original studies have reported the effect of CEA levels on prognosis in CRCLM patients, currently there is still no meta-analysis of the correlation between serum CEA and prognosis of CRCLM. Therefore, this was the first meta-analysis to investigate the effect of pre- and post-LR serum CEA levels on prognosis in CRCLM patients. A retrospective analysis of clinical data and experimental results from 36 studies involving 11143 CRCLM patients found that high levels of preoperative or postoperative serum CEA in patients who had received LR were mostly indicative of a poor prognosis. Firstly, CRCLM patients with higher levels of pre- or post-LR serum CEA had poor OS and were not affected by patient source, treatment modality, or cut-off values. Secondly, high pre-LR serum CEA levels also predicted shorter RFS (P < 0.001), which was also confirmed by the results of subgroups of the Asian population, patients receiving LR alone, multivariate analysis, the ≤ 5 ng/mL, and the 5-50 ng/mL. Because of high heterogeneity of the summary results of the meta-analysis in the DFS group, subgroup analysis was performed, and the results showed that high pre-LR serum CEA levels were significantly correlated with poor DFS in the group receiving LR alone (P < 0.05) and the group included in multivariate analysis (P < 0.05). Finally, regarding postoperative serum CEA predicting DFS and RFS, there were only two studies on each of them, so the evidence obtained so far in this study can only suggest that there may be potential for postoperative serum CEA to predict DFS and RFS in CRCLM patients, which needs to be confirmed by more future studies. CEA is a highly glycosylated cell surface protein that is an immunoglobulin superfamily cell adhesion molecule. Different glycosylation patterns result in different molecular weights in normal and cancer cells. CEA is attached to the cell membrane surface via a glycosylphosphatidylinositol (GPI) anchor, which can be cleaved by GPI-specific phospholipase D to release CEA from the membrane to cause it to be shed[73]. CEA can inhibit the death of circulating tumor cells: On the one hand, it protects circulating colon cancer cells from death in the blood or prevents circulating cell death as a general inhibitor of anoikis[74,75]; on the other hand, it binds to the heterogeneous nuclear RNA binding protein M4, a receptor protein in macrophages (Kupffer cells) that protect the liver, and activates Kupffer cells to secrete various cytokines that alter the liver microenvironment to facilitate cancer cell survival[76]. Subsequently, CEA upregulates cell adhesion molecules for metastasis, such as promoting migration of CRC cells, especially to the liver, which can be measured in the serum of cancer patients[77]. Therefore, increased CEA may mean that cancer cells are occurring or developing. Serum CEA levels are therefore measured to predict the occurrence, development, and prognosis of cancer.

In this study, the effect of preoperative and postoperative serum CEA levels on prognosis in CRCLM patients receiving LR was evaluated, and subgroup analysis was performed in terms of several potential influencing factors. Regarding preoperative results, it was found that the analysis modality (univariate/multivariate/survival curve) was the only factor contributing to a difference in OS results in this study, which might be due to the fact that univariate analysis did not exclude the effect of confounding factors that caused the difference in the results. For DFS, only 4 studies were included, and the small sample size was possibly the most influential factor on heterogeneity and results; in addition, the analysis modality, treatment modality and cut-off values might partially contribute to high heterogeneity and had potential effects on the results. For RFS, CRCLM itself is a highly malignant disease prone to recur, so there might be more factors influencing RFS, and at least the number of studies, treatment modality, analysis modality and cut-off values were found to potentially affect both outcomes and heterogeneity. Regarding postoperative results, the OS group had high heterogeneity, which was possibly due to the analysis modality. The preoperative and postoperative predictive outcomes remained basically consistent except for DFS, which was possibly due to the inclusion of too few studies. Finally, the use of neoadjuvant or adjuvant chemotherapy drugs before or after LR may alter CEA levels, thereby affecting the prognosis of patients with CRCLM. Relevant studies have shown that neoadjuvant chemotherapy can reduce CEA levels by eliminating potential tumor micrometastases; additionally, CEA levels can temporarily increase during adjuvant chemotherapy, possibly because cancer cells are effectively killed, leading to the release of CEA into the blood[78,79].

Since its discovery, CEA has been gradually shown to be overexpressed in most human cancers[80]. It was initially considered a tumor marker specific for colon/rectal cancer, and later increased CEA was also found in lung/breast/thyroid cancers and other cancers. Currently, CEA is often used as a serum tumor marker for the diagnosis of CRC or CRCLM[81]. The prognostic value of CEA in CRCLM patients has been confirmed in a variety of treatment modalities besides LR. Peng et al[82] reported that CEA levels might be a valuable prognostic factor for early recurrence in CRCLM patients after microwave ablation. Weiner et al[83] found that lower CEA levels were independently correlated with a higher survival rate in CRCLM patients treated with yttrium-90 radioembolization. Recent studies have found that CEA could predict preoperative lymph node metastasis in patients with thyroid cancer, preoperative progression-free survival and OS in patients with lung cancer, and postoperative OS in patients with esophageal cancer[84-86]. Currently prediction of outcome in CRCLM patients after LR remains a major challenge, so identification of preoperative and postoperative levels of the marker of poor prognosis may improve prognosis in CRCLM patients to some extent and facilitate better management and treatment.

However, potential limitations of this study have to be considered. Firstly, CEA was reported to be correlated with clinicopathological parameters[87], and some of the univariate studies we included did not eliminate the effect of confounding factors, which may lead to overestimated effect sizes. Secondly, the cut-off values of serum CEA in the included studies ranged from 4-200 ng/mL, which may be due to different approaches to measurement but may have a certain impact on the effect value. Therefore, further research is needed to standardize the cut-off value. Thirdly, it is a pity that there were few original studies on postoperative serum CEA to predict patient prognosis. Despite the limitations, our study has certain implications for clinical practice.

CONCLUSION

High pre-LR and post-LR serum CEA levels were significantly correlated with a poor prognosis in CRCLM patients, especially poor OS.

ARTICLE HIGHLIGHTS

Research background

Carcinoembryonic antigen (CEA), also known as CD66e, is a glycoprotein consisting of about 100 amino acid residues, produced and secreted by gastrointestinal epithelial cells, and it is one of the most widely used tumor markers worldwide. It had been reported that the initial level of CEA was closely related to the prognosis of colorectal cancer (CRC) patients after liver resection (LR).

Research motivation

This paper explored whether serum CEA in CRC liver metastasis (CRCLM) patients receiving LR played a significant predictive and prognostic role before and after surgery by summarizing currently available research data, so as to provide a scientific basis for further improving the prognosis in CRCLM patients.

Research objectives

This object of this paper is to explore whether serum CEA in CRCLM patients receiving LR played a significant predictive and prognostic role before and after surgery by summarizing currently available research data, so as to provide a scientific basis for further improving the prognosis in CRCLM patients.

Research methods

PubMed, Embase, Cochrane and Web of Science were searched with a time frame until February 27, 2023. The retrieved studies were imported into Endnote X9, and then, duplicate references were excluded automatically by the software and manually. After literature screening was completed, an Excel data extraction form specific to this study was developed to summarize the information on the included articles. The data were pooled and analyzed using Stata 16.0.

Research results

This study included 36 studies involving a total of 11143 CRCLM patients. The results showed that a high pre-LR serum CEA level was correlated with poor overall survival (OS) [hazard ratio (HR) = 1.61, 95% confidence interval (CI): 1.49-1.75, P < 0.001] and recurrence-free survival (RFS) (HR = 1.27, 95%CI: 1.11-1.45, P < 0.001) in CRCLM patients. A high post-LR serum CEA level predicted poor OS (HR = 2.66, 95%CI: 2.10-3.38, P < 0.001).

Research conclusions

High serum CEA levels in CRCLM patients were significantly associated with poor OS before and after LR surgery.

Research perspectives

Regarding postoperative serum CEA predicting disease-free survival (DFS) and RFS, there were only two studies on each of them, so the evidence obtained so far in this study can only suggest that there may be potential for postoperative serum CEA to predict DFS and RFS in CRCLM patients, which needs to be confirmed by more future studies.